iShares International Treasury Bond ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? iShares International Treasury Bond ETF trades at $39.74 (market cap $1.30B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 19.4× iShares International Treasury Bond ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| IGOV | RPRX | |
|---|---|---|
Market Cap | $1.30B | $25.27B |
Volume | 693,740 | 3,671,183 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $63.96 |
52-Week Low | $39.65 | $35.44 |
Typical Hold Time | 92 Days | 1 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.73, up 0.08% on the day, with a bearish technical signal from moving averages but neutral oscillators. Key financial ratios such as P/E and P/S are not available in the provided data. Recent news highlights rising global bond yields, which may impact interest-rate-sensitive assets.
The outlook remains cautious due to bearish technicals and macroeconomic pressures from higher yields. Investment opportunities hinge on undisclosed fundamentals, while risks include market volatility and interest rate sensitivity. Investors should await clearer financial disclosures for a full assessment.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →